{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:49:13Z","timestamp":1790534953433,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,11,29]],"date-time":"2014-11-29T00:00:00Z","timestamp":1417219200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/s12913-014-0595-0","type":"journal-article","created":{"date-parts":[[2014,11,28]],"date-time":"2014-11-28T19:09:02Z","timestamp":1417201742000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["International comparison of the factors influencing reimbursement of targeted anti-cancer drugs"],"prefix":"10.1186","volume":"14","author":[{"given":"Carol Sunghye","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Gyoo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngil","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Seog","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,29]]},"reference":[{"issue":"6","key":"595_CR1","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMhpr0807774","volume":"360","author":"PB Bach","year":"2009","unstructured":"Bach PB: Limits on Medicare\u2019s ability to control rising spending on cancer drugs. N Engl J Med. 2009, 360 (6): 626-633. 10.1056\/NEJMhpr0807774.","journal-title":"N Engl J Med"},{"issue":"10","key":"595_CR2","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.mayocp.2012.07.007","volume":"87","author":"M Siddiqui","year":"2012","unstructured":"Siddiqui M, Rajkumar SV: The high cost of cancer drugs and what we can do about it. Mayo Clin Proc. 2012, 87 (10): 935-943. 10.1016\/j.mayocp.2012.07.007.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"595_CR3","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1200\/JCO.2006.07.8956","volume":"25","author":"MF Drummond","year":"2007","unstructured":"Drummond MF, Mason AR: European perspective on the costs and cost-effectiveness of cancer therapies. J Clin Oncol. 2007, 25 (2): 191-195. 10.1200\/JCO.2006.07.8956.","journal-title":"J Clin Oncol"},{"issue":"2","key":"595_CR4","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/JCO.2006.09.6081","volume":"25","author":"NJ Meropol","year":"2007","unstructured":"Meropol NJ, Schulman KA: Cost of cancer care: issues and implications. J Clin Oncol. 2007, 25 (2): 180-186. 10.1200\/JCO.2006.09.6081.","journal-title":"J Clin Oncol"},{"issue":"1","key":"595_CR5","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/1078155210389218","volume":"18","author":"P Savage","year":"2012","unstructured":"Savage P: Development and economic trends in cancer therapeutic drugs in the UK from 1955 to 2009. J Oncol Pharm Pract. 2012, 18 (1): 52-56. 10.1177\/1078155210389218.","journal-title":"J Oncol Pharm Pract"},{"issue":"9","key":"595_CR6","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S1470-2045(07)70250-4","volume":"8","author":"M Rawlins","year":"2007","unstructured":"Rawlins M: Paying for modern cancer care\u2013a global perspective. Lancet Oncol. 2007, 8 (9): 749-751. 10.1016\/S1470-2045(07)70250-4.","journal-title":"Lancet Oncol"},{"issue":"15","key":"595_CR7","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1093\/jnci\/djp177","volume":"101","author":"T Fojo","year":"2009","unstructured":"Fojo T, Grady C: How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst. 2009, 101 (15): 1044-1048. 10.1093\/jnci\/djp177.","journal-title":"J Natl Cancer Inst"},{"issue":"28","key":"595_CR8","doi-asserted-by":"publisher","first-page":"4506","DOI":"10.1200\/JCO.2007.13.0401","volume":"25","author":"RA Miksad","year":"2007","unstructured":"Miksad RA, Schnipper L, Goldstein M: Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value?. J Clin Oncol. 2007, 25 (28): 4506-4507. 10.1200\/JCO.2007.13.0401. author reply 4508","journal-title":"J Clin Oncol"},{"issue":"15","key":"595_CR9","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","volume":"25","author":"MJ Moore","year":"2007","unstructured":"Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007, 25 (15): 1960-1966. 10.1200\/JCO.2006.07.9525.","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"595_CR10","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1111\/j.1524-4733.2009.00557.x","volume":"12","author":"SD Sullivan","year":"2009","unstructured":"Sullivan SD, Watkins J, Sweet B, Ramsey SD: Health technology assessment in health-care decisions in the United States. Value Health. 2009, 12 (Suppl 2): S39-S44. 10.1111\/j.1524-4733.2009.00557.x.","journal-title":"Value Health"},{"issue":"4","key":"595_CR11","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1470-2045(03)01036-2","volume":"4","author":"P Littlejohns","year":"2003","unstructured":"Littlejohns P, Barnett D, Longson C: Excellence UKNIfC: the cancer technology appraisal programme of the UK\u2019s National Institute for Clinical Excellence. Lancet Oncol. 2003, 4 (4): 242-250. 10.1016\/S1470-2045(03)01036-2.","journal-title":"Lancet Oncol"},{"key":"595_CR12","volume-title":"Health Technology Assessment and Health Policy-making in Europe: Current Status, Challenges and Potential","author":"M Velasco-Garrido","year":"2008","unstructured":"Velasco-Garrido M, Kristensen FB, Nielsen CP, Busse R: Health Technology Assessment and Health Policy-making in Europe: Current Status, Challenges and Potential. 2008, European Observatory on Health Systems and Policies, Copenhagen"},{"issue":"3","key":"595_CR13","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.3747\/co.19.946","volume":"19","author":"PK Cheema","year":"2012","unstructured":"Cheema PK, Gavura S, Migus M, Godman B, Yeung L, Trudeau ME: International variability in the reimbursement of cancer drugs by publically funded drug programs. Curr Oncol. 2012, 19 (3): e165-e176. 10.3747\/co.19.946.","journal-title":"Curr Oncol"},{"issue":"6","key":"595_CR14","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/S0149-2918(98)80115-X","volume":"20","author":"CD Mullins","year":"1998","unstructured":"Mullins CD, Ogilvie S: Emerging standardization in pharmacoeconomics. Clin Ther. 1998, 20 (6): 1194-1202. 10.1016\/S0149-2918(98)80115-X. discussion 1192\u20131193","journal-title":"Clin Ther"},{"key":"595_CR15","unstructured":"Department of Health and Ageing (DHA) Pharmaceutical Benefits Scheme. [Available online at: ; cited May 10, 2013], [http:\/\/www.pbs.gov.au\/pbs\/home]"},{"key":"595_CR16","unstructured":"Ontario Guidelines for Economic Analysis of Pharmaceutical Products. [Available online at: ; cited May 10, 2013], [http:\/\/www.health.gov.on.ca\/en\/pro\/programs\/drugs\/dsguide\/docs\/economic.pdf]"},{"key":"595_CR17","unstructured":"New Drug Funding Program. [Available online at: ; cited May 10, 2013] , [https:\/\/www.cancercare.on.ca\/toolbox\/drugs\/ndfp]"},{"key":"595_CR18","unstructured":"Drugs funded by Ontario Drug Benefit (ODB) Program. [Available online at: ; May 10, 2013], [http:\/\/www.health.gov.on.ca\/en\/pro\/programs\/drugs\/odbf_eformulary.aspx]"},{"key":"595_CR19","unstructured":"Ministry of Health and Long-Term Care Ontario Public Drug Programs: Exceptional Access Program. [Available online at: ; cited May 10, 2013], [http:\/\/www.health.gov.on.ca\/en\/pro\/programs\/drugs\/eap_mn.aspx]"},{"key":"595_CR20","unstructured":"The Haute Autorit\u00e9 de sant\u00e9. [Available online at: ; cited May 10, 2013], [http:\/\/www.has-sante.fr\/]"},{"key":"595_CR21","unstructured":"Gemeinsamer Bundesausschuss. [Available online at: ; cited May 10, 2013], [http:\/\/www.g-ba.de\/]"},{"key":"595_CR22","unstructured":"Institute for Quality & Efficiency in Health Care. [Available online at: ; cited May 10, 2013], [https:\/\/www.iqwig.de\/]"},{"key":"595_CR23","unstructured":"Pharmaceuticals and Medical Device Agency (PMDA) Approved Products. [Available online at: ; cited May 10, 2013], [http:\/\/www.pmda.go.jp\/english\/service\/approved.html]"},{"key":"595_CR24","unstructured":"Reimbursement criteria for anti-cancer drugs. [Available online at: ; cited May 10, 2013], [http:\/\/www.hira.or.kr\/eng\/index.html]"},{"key":"595_CR25","unstructured":"L\u00e4kemedelsf\u00f6rm\u00e5nsn\u00e4mnden. [Available online at: ; cited May 10, 2013], [http:\/\/www.tlv.se\/]"},{"key":"595_CR26","unstructured":"Bureau of National Health Insurance, Department of Health, Execitive Yuan. [Available online at: ; cited May 10, 2013], [http:\/\/www.nhi.gov.tw\/]"},{"key":"595_CR27","unstructured":"National Institute for Health and Clinical Excellence (NICE) Guidance. [Available online at: ; cited May 10, 2013], [http:\/\/guidance.nice.org.uk]"},{"key":"595_CR28","unstructured":"FDA Approved Drug Products. [Available online at: ; cited May 10, 2013], [http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm]"},{"issue":"20","key":"595_CR29","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1200\/JCO.2009.26.2758","volume":"28","author":"A Mason","year":"2010","unstructured":"Mason A, Drummond M, Ramsey S, Campbell J, Raisch D: Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric?. J Clin Oncol. 2010, 28 (20): 3234-3238. 10.1200\/JCO.2009.26.2758.","journal-title":"J Clin Oncol"},{"key":"595_CR30","volume-title":"The Economics of Health and Health Care","author":"SGA Folland","year":"2010","unstructured":"Folland SGA, Stano M: Chapter 4: Economic Effiencey and Cost-Benefit Analysis. The Economics of Health and Health Care. 2010, Prentice Hall, Boston, 6","edition":"6"},{"key":"595_CR31","doi-asserted-by":"crossref","unstructured":"Wagstaff A: Social health insurance vs. tax-financed health systems-evidence from the OECD. World Bank Policy Research Working Paper Series, Vol 2009 .","DOI":"10.1596\/1813-9450-4821"},{"key":"595_CR32","unstructured":"OECD Health Data 2012. [Available online at: ; cited May 10, 2013], [http:\/\/www.pbs.gov.au\/html\/home]"},{"key":"595_CR33","volume-title":"Making choices in health : WHO guide to cost-effectiveness analysis","author":"TT-T Edejer","year":"2003","unstructured":"Edejer TT-T: Making choices in health : WHO guide to cost-effectiveness analysis. 2003, World Health Organization, Geneva"},{"key":"595_CR34","unstructured":"Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal). [Available online at: ; cited May 10, 2013], [http:\/\/www.nice.org.uk\/guidance\/TA148]"},{"key":"595_CR35","unstructured":"Public Summary Documents by Product in Pharmaceutical Benefits Scheme (PBS). [Available online at: ; cited May 10, 2013], [http:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/2011-03\/pbac-psd-bevacizumab-march11]"},{"issue":"5","key":"595_CR36","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1524-4733.2005.00045.x","volume":"8","author":"S Ramsey","year":"2005","unstructured":"Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, Cook J, Glick H, Liljas B, Petitti D, Reed S: Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health. 2005, 8 (5): 521-533. 10.1111\/j.1524-4733.2005.00045.x.","journal-title":"Value Health"},{"key":"595_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/1-4020-5511-0","volume-title":"EQ-5D value sets: inventory, comparative review and user guide, vol. 2","author":"A Szende","year":"2007","unstructured":"Szende A, Oppe M, Devlin NJ: EQ-5D value sets: inventory, comparative review and user guide, vol. 2. 2007, Springer, Dordrecht"},{"issue":"4","key":"595_CR38","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/j.1468-0009.2009.00579.x","volume":"87","author":"RR Faden","year":"2009","unstructured":"Faden RR, Chalkidou K, Appleby J, Waters HR, Leider JP: Expensive cancer drugs: a comparison between the United States and the United Kingdom. Milbank Q. 2009, 87 (4): 789-819. 10.1111\/j.1468-0009.2009.00579.x.","journal-title":"Milbank Q"},{"key":"595_CR39","volume-title":"Centre for Health Economics, University of York","author":"C Karl","year":"2013","unstructured":"Karl C, Steve M, Marta S, Nigel R, Eldon S, Sebastian H, Nancy D, Peter CS, Mark S: Methods for the estimation of the NICE cost effectiveness threshold. Centre for Health Economics, University of York. 2013"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12913-014-0595-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-014-0595-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-014-0595-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-014-0595-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T06:40:31Z","timestamp":1630564831000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-014-0595-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,29]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["595"],"URL":"https:\/\/doi.org\/10.1186\/s12913-014-0595-0","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,29]]},"assertion":[{"value":"21 March 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"595"}}